AI Article Synopsis
- Treatment options for anaplastic thyroid cancer (ATC) and refractory papillary thyroid carcinoma (PTC) are currently limited, resulting in poor patient outcomes.
- The study identified intercellular adhesion molecule-1 (ICAM1) as a promising target and developed two ICAM1-directed antibody-drug conjugates (I1-MMAE and I1-DXd) that effectively target and eliminate ATC and PTC cells while sparing healthy cells.
- Additionally, the research proposed using MRI as a non-invasive method to monitor ICAM1 expression in thyroid tumors, supporting the potential for I1-MMAE and I1-DXd as new treatment options for advanced thyroid cancers.
Article Abstract
Treatment options for anaplastic thyroid cancer (ATC) and refractory papillary thyroid carcinoma (PTC) are limited and outcomes remain poor. In this study, we determined via bioinformatic expression analyses and immunohistochemistry staining that intercellular adhesion molecule-1(ICAM1) is an attractive target for ATC and PTC. We designed and engineered two ICAM1-directed antibody-drug conjugate (I1-MMAE and I1-DXd), both of which potently and selectively ablate multiple human ATC and PTC cell lines without affecting non-plastic cells . Furthermore, I1-MMAE and I1-DXd mediated a potent tumor regression in ATC and PTC xenograft models. To develop a precision medicine, we also explored magnetic resonance imaging (MRI) as a non-invasive biomarker detection method to quantitatively map ICAM1 antigen expression in heterogeneous thyroid tumors. Taken together, this study provides a strong rationale for the further development of I1-MMAE and I1-DXd as promising therapeutic candidates to treat advanced PTC and ATC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371847 | PMC |
| http://dx.doi.org/10.1016/j.isci.2023.107272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!